Neurocrine biosciences announces positive top-line data from phase 3 study of crinecerfont in adults for the treatment of congenital adrenal hyperplasia (cah)

Cahtalyst ™ met primary endpoint demonstrating a statistically significant decrease from baseline daily glucocorticoid dose with androgen control key secondary endpoint achieved statistically significant decrease in androstenedione at week 4 versus placebo  key secondary endpoint demonstrated a statistically significant number of patients on crinecerfont achieved a reduction to a physiologic glucocorticoid dose versus placebo crinecerfont was generally well-tolerated  san diego , sept. 12, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced positive top-line data from the phase 3 cahtalyst™ adult study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency (21-ohd).
NBIX Ratings Summary
NBIX Quant Ranking